Navigation Links
Growth hormone treatment for children may exacerbate feelings of depression
Date:6/23/2014

CHICAGO, IL Short, otherwise healthy children who are treated with growth hormone (GH) may become taller, but they may also become more depressed and withdrawn over time, compared to children the same age and height who are not treated with GH, a new study finds. The results were presented in a poster Monday, June 23 at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society in Chicago.

"Daily injections, frequent clinic visits and repeated discussions about height might exacerbate instead of improve psychosocial concerns in children with idiopathic short stature (ISS) who are otherwise healthy, and give them no cognitive improvements," said lead author Emily C. Walvoord, MD, associate professor of clinical pediatrics at the Indiana University School of Medicine in Indianapolis.

While the link between using GH to increase height and improved psychological adaptation is being debated, early data suggest that the subtle cognitive problems seen in adults with growth hormone deficiency (GHD) might also occur in children with GHD and might improve with treatment.

Dr. Walvoord and her colleagues evaluated the cognitive and behavioral status of children with GHD and ISS after they received either GH therapy or observation alone, and their preliminary results presented here challenge the idea that improvements in height also result in improvements in psychological functioning. Their findings also raise the concern that GH treatment of these otherwise healthy children might even worsen their emotional symptoms.

In their study, 41 children with GHD and ISS between the ages of 6 and 16 years of age, 11 on average, took a series of tests that examined their cognitive functioning, and their parents completed questionnaires that assessed their child's emotional and behavioral functioning.

The children were then assigned to either the group that was treated with growth hormone or the untreated control group, and after 9 to 12 months, the children in both groups were retested.

So far, 41 children have had initial testing and 28 have had follow up testing. Among these children, the researchers have found no differences in cognitive functioning between GHD and the ISS children from their first test to their retest.

However, compared with the untreated ISS children, whose depression and withdrawal according to their parents' questionnaire responses have lessened over that period, the depression and withdrawal symptoms in the treated GHD and ISS children have worsened.

"This novel study of the cognitive and emotional effects of GH therapy in children with GHD and ISS compared to untreated short children raises concerns that, despite improvements in height, these children may not achieve psychosocial benefits," Dr. Walvoord said.


'/>"/>

Contact: Aaron Lohr
alohr@endocrine.org
202-971-3654
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Breakthrough drug-eluting patch stops scar growth and reduces scar tissues
2. Growth hormone defect may protect against diabetes, cancer in unique ecuador population
3. Finding the Achilles Heel of ovarian tumor growth
4. Shrub growth decreases as winter temperatures fluctuate up
5. Scientists slow brain tumor growth in mice
6. Revealed:Proteins role in preventing heart muscle growth leading to heart failure
7. Breastfeeding promotes the growth of beneficial bacteria in the gut
8. Willetts announces new Engineering Fellowships for Growth
9. Scientists discover a new way to enhance nerve growth following injury
10. Scientists find key steps linking dietary fats and colon cancer tumor growth
11. Scaffolding protein promotes growth and metastases of epithelial ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... 2017 , ... CGL Electronic Security Inc., an Electronic Security Products and Services ... LLC. , The new CGL Technologies, LLC office is located in Philadelphia and ... whom have creative business development methods, who are responsive to the needs of their ...
(Date:9/26/2017)... , ... September 26, 2017 ... ... Guide for Drug and Device Manufacturers, **An FDAnews Management Report**, http://www.fdanews.com/products/54648-principles-of-equipment-qualification ... equipment qualification. , Manufacturers must prove that their equipment, operations and ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... ... LLC and expands services in Northern Colorado. Aspire Autism, A Division of Autism ... Applied Behavior Analysis (ABA) services. Aspire provides center based Autism services in Broomfield ...
(Date:9/26/2017)... ... 2017 , ... “How to Live in the Millennium”: a gripping take on how the ... longer a part of everyday life and do not affect daily choices. It shows ... the thoughts, words, and actions that are chosen. “How to Live in the Millennium” ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Childhood Memories of a Virginia ... readers back, and help them relive their own youth. “Childhood Memories of a Virginia ... in the US Navy for nine years. He received his BS from Idaho ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a ... it will host an educational session focused on the ... infection (CLABSI) prevention at the 2017 Annual Scientific Meeting ... will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly and ... will present new data for galcanezumab and lasmiditan, two ... the International Headache Society (IHC) taking place Sept. 7-10 ... Lilly will highlight new, long-term data from an open-label ... of galcanezumab (120 mg and 240 mg) for the ...
(Date:9/5/2017)... 2017  Xyntek Inc. has announced another milestone in their continued growth and ... meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, Suite 1528, ... Xyntek's recently ... ...
Breaking Medicine Technology: